Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by Weebleon Jul 29, 2018 9:32pm

108 Views

Post# 28383551

RE:RE:Up in pre-market today probable because of this US patent?

Geez, and all along I thought they could skip the rules and sell drugs that weren't approved. Thanks for stating the obvious.

Only a moron would waste so much time bashing a stock day after day in which they have a position. So are you a moron or actually buying or a short? Or are you working for somebody?

Bullboard Posts

Sirios Resource discovers visible gold in Quebec